<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H06856C5BA645423FB5CA1699AE8174EE" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 4084 IH: To repeal the amendments made to the Controlled Substances Act by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-10-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4084</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20171019">October 19, 2017</action-date><action-desc><sponsor name-id="K000382">Ms. Kuster of New Hampshire</sponsor> (for herself, <cosponsor name-id="J000297">Mr. Jenkins of West Virginia</cosponsor>, <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>, and <cosponsor name-id="C000754">Mr. Cooper</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To repeal the amendments made to the Controlled Substances Act by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.</official-title></form><legis-body id="H91D0B60BFA2D4154BEB2216C10ACBE0A" style="OLC"> 
<section id="H47A370CFE25649DB932BE756C5C8B5E2" section-type="section-one"><enum>1.</enum><header>Repeal of the Ensuring Patient Access and Effective Drug Enforcement Act of 2016</header>
<subsection id="H527328A33FC647EE995211241A2656F1"><enum>(a)</enum><header>Registration process under the Controlled Substances Act</header><text display-inline="yes-display-inline">Sections 1 and 2 of the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (<external-xref legal-doc="public-law" parsable-cite="pl/114/145">Public Law 114–145</external-xref>; 130 Stat. 354) and the amendments made by such sections are repealed.</text></subsection> <subsection id="H705465B58A9F443D85ECBBEA0C0188D4"><enum>(b)</enum><header>Technical and conforming amendments</header> <paragraph id="H5AE77C860FF842408DF4E6AD70900841"><enum>(1)</enum><header>Definitions</header> <subparagraph id="HD8BCDFF2E1B14917969E2B1B98788198"><enum>(A)</enum><header>Factors as may be relevant to and consistent with the public health and safety</header><text>Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>) is amended by striking subsection (j).</text></subparagraph>
<subparagraph id="H46CCB41BF9C84985BF4D32D2FF4772CC"><enum>(B)</enum><header>Imminent danger to the public health or safety</header><text>Section 304(d) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/824">21 U.S.C. 824(d)</external-xref>) is amended—</text> <clause id="H04008C48D8CB45DE87FB6271713BD2E9"><enum>(i)</enum><text>by striking <quote>(d)(1) The Attorney General</quote> and inserting <quote>(d) The Attorney General</quote>; and</text></clause>
<clause id="H6E6ADB8119094EC7A1FD7FAE7A382FD0"><enum>(ii)</enum><text>by striking paragraph (2).</text></clause></subparagraph></paragraph> <paragraph id="HDB4356D3DE5944E2A156CECED13A957D"><enum>(2)</enum><header>Opportunity to submit corrective action plan prior to revocation or suspension</header><text>Section 304(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/824">21 U.S.C. 824(c)</external-xref>) is amended—</text>
<subparagraph id="H39226D5584454040A1261FB35325296C"><enum>(A)</enum><text>by striking paragraphs (2) through (5);</text></subparagraph> <subparagraph id="HD6CAA88AF3FF46C2B16D27D254E51809"><enum>(B)</enum><text>by striking <quote>(c)(1) Before</quote> and inserting <quote>(c) Before</quote>; and</text></subparagraph>
<subparagraph commented="no" display-inline="no-display-inline" id="HED0C0604497E45ED9CEA6C164EB7746A"><enum>(C)</enum><text>by adding at the end the following: <quote>The order to show cause shall contain a statement of the basis thereof and shall call upon the applicant or registrant to appear before the Attorney General at a time and place stated in the order, but in no event less than thirty days after the date of receipt of the order. Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance with subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/5/5">chapter 5</external-xref> of title 5, United States Code. Such proceedings shall be independent of, and not in lieu of, criminal prosecutions or other proceedings under this title or any other law of the United States.</quote>.</text></subparagraph></paragraph></subsection></section> </legis-body></bill>

